[Repaglinide (NN-623)].
Matsuda
Masafumi
M
Diabetes and Endocrine Division, Department of Medicine, Kawasaki Medical School.
Kaku
Kohei
K
D000255:Adenosine Triphosphate / Q000378:metabolism; D000284:Administration, Oral; D015220:Calcium Channels / Q000378:metabolism; D002219:Carbamates / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000378:metabolism; D010880:Piperidines / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology; D015221:Potassium Channels / Q000378:metabolism
D015220:Calcium Channels; D002219:Carbamates; D007004:Hypoglycemic Agents; D007328:Insulin; D010880:Piperidines; D015221:Potassium Channels; C072379:repaglinide; D000255:Adenosine Triphosphate